Start of the international large-scale project TransBioLine
The Innovative Medicines Initiative (IMI) announced the launch of the Translational Safety Biomarker Pipeline (TransBioLine) Project, a five-year program to generate exploratory and confirmatory data supporting regulatory qualification and acceptance of novel safety biomarkers for five target organ systems (kidney, liver, pancreas, vascular, and central nervous system, CNS) for application in drug development.
The TransBioLine Project is a consortium of 27 partners across pharmaceutical companies, small and medium-sized enterprises, and academic institutions from 10 European countries, and is coordinated by the University of Zurich with Pfizer Inc. as the industry lead. It is funded by the IMI Joint Undertaking as a public-private partnership, with a budget of 28M€ and will be active through 2024.
The Central Biobank Charité (ZeBanC) and the Department of Neurology are involved in this huge international project. Prof. Dr. Michael Hummel, head of the ZeBanC, is happy to announce that the ZeBanC is coordinating the sample-related processes, the provision of sample kits, storage and distribution of samples to the analysis laboratories. The samples with the corresponding sample data will be securely stored according to ethical and data protections aspects. PD Dr. Klemens Ruprecht, department of Neurology is principle investigator for the work package dealing with biomarkers for drug induced CNS injury. The contribution of the Charité, which is very important for the success of the TransBioLine project, is supported with 1.8 million Euro.
The Innovative Medicines Initiative is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). It is working to improve health by speeding up the development of the next generation of medicines, particularly in areas where there is an unmet medical or social need.
Back to Overview